focus -WSS

focus

author：explore 2025-10-02 19:20:48 - browse：44

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： A fraught question for the kids of Alzheimer’s: Is it coming for us?

WSS

How doctors and nurses shape Google's AI

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Ionis drug prevents swelling attacks due to hereditary angioedema

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

How to increase colonoscopy rates? Looks like an AI can help

Nick Jonas talks about managing diabetes along with his career

explore

focus

leisure time

Virginia high school admissions case could be legal follow

The Pandemic Treaty must support building strong health systems

Peter Hotez and the public health issue of online harassment

NIH documents show early flaws of $1.6 billion long Covid program

Alkermes shareholders re

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Novavax promises a turnaround & Lilly roils the obesity market

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

New air purifier tech could be key to improving indoor air quality

Medicare to cover more brain scans related to Alzheimer’s drugs

knowledge

How doctors and nurses shape Google's AI

Wellcome Trust names Røttingen as its new CEO

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Woman returns to dialysis after doctors remove transplanted pig kidney

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO: Palliative care found as helpful given virtually as in person

leisure time

hotspot

entertainment

hotspot